Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-02-13 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes exhibits related to an underwriting agreement, legal opinions, consents, and an announcement of the closing of a public offering of American Depository Shares. The document length is 2535 characters, which is relatively short and primarily serves as a regulatory filing to disclose financing activity and related legal documents. It does not contain detailed financial statements or comprehensive financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it does not fit the criteria for a full financial report or a capital/financing update announcement by itself, but rather a formal SEC filing with attached exhibits and announcements.
2015-02-13 English
SCHEDULE 13G/A
Major Shareholding Notification
2015-02-13 English
SCHEDULE 13G/A
Major Shareholding Notification
2015-02-13 English
SCHEDULE 13G/A
Major Shareholding Notification
2015-02-13 English
SCHEDULE 13G/A
Major Shareholding Notification
2015-02-13 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a presentation at a conference, but does not contain financial statements or detailed financial data. The document length is short (2314 characters) and it primarily serves as a regulatory announcement of an event (presentation) rather than a full report. According to the rules, such filings that are announcements or contain press releases without substantive financial data are best classified as Regulatory Filings (RNS).
2015-02-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.